Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

BACKGROUND: We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer. METHODS: TeloVac was a three-group, open-label, randomised phase 3 trial. We rec...

Full description

Bibliographic Details
Main Authors: Middleton, Gary, Silcocks, Paul, Cox, Trevor, Valle, Juan, Wadsley, Jonathan, Propper, David, Coxon, Fareeda, Ross, Paul, Srinivasan, Madhusudan, Roques, Tom, Cunningham, David, Falk, Stephen, Wadd, Nick, Harrison, Mark, Corrie, Pippa, Iveson, Tim, Robinson, Angus, McAdam, Karen, Eatock, Martin, Evans, Jeff, Archer, Caroline, Hickish, Tamas, Garcia-Alonso, Angel, Nicolson, Marianne, Steward, William, Anthoney, D. Alan, Greenhalf, William, Shaw, Victoria E., Costello, Eithne, Naisbitt, Dean, Rawcliffe, Charlotte, Nanson, Gemma, Neoptolemos, John P.
Format: Article
Published: Elsevier 2014
Subjects:
Copyright Elsevier 2014.
Online Access:https://eprints.nottingham.ac.uk/43066/

Internet

https://eprints.nottingham.ac.uk/43066/

Similar Items